title: [Study on the relationship between concentrations of 5-FU and PyNPase activity in tumor tissue during oral 5'-DFUR treatment in patients with advanced colorectal cancer].
abstract: Fifty-three patients with advanced colorectal cancer were given single oral doses of 5'-DFUR, 400 mg/body, preoperatively to assess the pharmacokinetics of 5'-DFUR in the patients with colorectal cancer and to investigate schedules for 5'-DFUR treatment. The time courses of PyNPase activity and 5-FU concentration in the resected tissue specimens were determined. This study indicated that: 1) High 5-FU concentration and PyNPase activity were noted in tumor tissue and lymph nodes. 2) Effective 5-FU concentration in tumor tissue was maintained even 24 hours after treatment. 3) Effective lymph node concentration of 5-FU was maintained even 8 hours after treatment. 4) PyNPase activity in tumor tissue was significantly higher than that in the normal intestinal mucosa (p < 0.05). These results suggest that 400 mg of 5'-DFUR at 8-hour intervals provides effective tissue concentrations of 5-FU for the treatment of patients with advanced colorectal cancer.
authors.affiliation: Institute of gastroenterological Surgery, Tokyo Women's Medical College.
authors.forename: K
authors.initials: K
authors.lastname: Watanabe
authors.forename: T
authors.initials: T
authors.lastname: Igarashi
authors.forename: M
authors.initials: M
authors.lastname: Suzuki
authors.forename: T
authors.initials: T
authors.lastname: Hayashi
authors.forename: K
authors.initials: K
authors.lastname: Yoshida
authors.forename: F
authors.initials: F
authors.lastname: Hanyu
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005472:Fluorouracil / Q000032:analysis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010430:Pentosyltransferases / Q000378:metabolism*; D057845:Pyrimidine Phosphorylases
chemical_list: D000970:Antineoplastic Agents; D005467:Floxuridine; D010430:Pentosyltransferases; D057845:Pyrimidine Phosphorylases; D005472:Fluorouracil; C025034:doxifluridine